Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — IN3 Medical Device Summit 2015
23 slides from Aethlon Medical's conference presentation, Nov 12, 2015
Slide 1: Therapeutic Partnering Opportunities
A e thlon Medical, Inc . Therapeutic Partnering Opportunities IN3 Medical Device Summit November 11, 2015 Jim Joyce Chairman, CEO
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the A e thlon ADAPT™ system, t
Slide 3: About Aethlon Medical
About A e thlon Medical • Nasdaq : AEMD • Headquartered in San Diego, California • We Create Affinity Biofiltration Devices to Treat Life - Threatening Diseases
Slide 4: Aethlon Affinity Biofiltration Technology
A e thlon Affinity Biofiltration Technology • Expansive Therapeutic Device Platform – The A e thlon ADAPT™ System • A daptive D ialysis - Like A ffinity P latform T echnology • Intersection of a ffinity c ompounds & advanced p lasma m embrane t echnologies • Rapid elimination of circulating disease
Slide 5: The Aethlon Hemopurifier
The A e thlon Hemopurifier® Single - Use Clearance of Viruses & Tumor - Secreted Exosomes
Slide 6: Deployed Within the Global Infrastructure of Dialysis & CRRT Machines
DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES
Slide 7: Unmet Needs in Infectious Disease
Unmet Needs in Infectious Disease • Antiviral Drug - R esistance • Untreatable Latent Viruses – Organ Transplant – Sepsis • DARPA DLT Program • Bioterror & Pandemic Threats – Leading broad - spectrum countermeasure
Slide 8: TIME Best Inventions of 2014
TIME Deo. 4/Dec. a 20g THE 25 BEST INVENTIONS OF 2014
Slide 9: Slide 9
Slide 10: Bioterror & Pandemic Validations
BIOTERROR & PANDEMIC VALIDATIONS Ebola Pandemic Influenza West Nile Pox Viruses Lassa Dengue
Slide 11: Human Treatment Experience
Human Treatment Experience HIV, Hepatitis - C and Ebola Virus
Slide 12: A Case Study of Hemopurifier Therapy Against an Untreatable Viral Pathogen
A Case Study of Hemopurifier ® Therapy Against an Untreatable Viral Pathogen
Slide 13: The Treatment of Ebola Virus
The Treatment of Ebola Virus Frankfurt University Hospital Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)
Slide 14: Hemopurifier Therapy Administration to a Comatose Ebola Patient
Hemopurifier® therapy administration to a comatose Ebola patient with multiple - organ failure
Slide 15: Dr. Stefan Büttner Holding Hemopurifier After Ebola Treatment
Dr. Stefan Büttner Holding Hemopurifier® After Ebola Treatment
Slide 16: Ebola Treatment Data Presented at American Society of Nephrology
Ebola Treatment Data Presented By Dr. Helmut Geiger American Society of Nephrology Annual Meeting • 6.5 hour Hemopurifier® therapy administration • Pre - treatment viral load: 400,000 copies/ml • Post - treatment viral load: 1,000 copies/ml • 242 million of Ebola viruses captured • Patient recovered
Slide 17: Application of the Hemopurifier in Cancer
Application of the Hemopurifier ® in Cancer SAVE LIVES
Slide 18: Hemopurifier Capture of Tumor-Secreted Exosomes
Hemopurifier ® Capture of Tumor - Secreted Exosomes
Slide 19: Tumor-Secreted Exosomes: A Significant Unmet Medical Need in Cancer
Tumor - Secreted Exosomes A Significant Unmet Medical Need in Cancer • Trigger apoptosis of immune c ells • Contribute to drug and chemotherapy resistance • Promote angiogenesis • Seed the creation and spread of metastasis • Exosome load correlates with stage of cancer
Slide 20: Partner to Establish a Pipeline of ADAPT-Based Therapies
AS WE CLINICALLY PROGRESS OUR HEMOPURIFIER®, WE WILL PARTNER TO ESTABLISH A PIPELINE OF ADAPT™ BASED THERAPIES
Slide 21: Disease Partnering Characteristics
Disease Partnering Characteristics • Must be a life - threatening disease • Limited or no proven therapeutic options • Indications affecting < 4000 per year may be given humanitarian/orphan consideration • Disease promoting factors must be accessible in the circulatory system – Single or multi - tar
Slide 22: Partnering Candidate Profile
Partnering Candidate Profile • Industry, VC and Institutional Healthcare Investors • Academic research teams • Therapeutic organizations interested in testing a device pathway for their affinity compounds
Slide 23: Contact
CONTACT: A e thlon Medical, Inc 9635 Granite Ridge Drive Suite 100 San Diego, California 92123 Jim Joyce Chairman & CEO jj@aethlonmedical.com 858.459.7800 x301